Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016).
Benedetta PellegrinoChiara TommasiOlga SerraStefania GoriElisabetta CretellaMassimo AmbroggiAntonio FrassoldatiGiancarlo BisagniChiara CasariniEmilio BriaLuisa CarbogninElena FiorioAntonella MuraClaudio ZamagniLorenzo GianniAlberto ZambelliFilippo MontemurroMichele TognettoRenata TodeschiniGabriele MissaleNicoletta CampaniniEnrico Maria SiliniGiuseppe MagliettaAntonino MusolinoPublished in: Journal for immunotherapy of cancer (2023)
NCT03144947, and EudraCT number: 2016-000435-41.
Keyphrases
- phase ii
- open label
- locally advanced
- phase iii
- positive breast cancer
- clinical trial
- rectal cancer
- phase ii study
- placebo controlled
- double blind
- squamous cell carcinoma
- study protocol
- neoadjuvant chemotherapy
- radiation therapy
- epidermal growth factor receptor
- randomized controlled trial
- metastatic breast cancer
- tyrosine kinase